Tools chosen: kalshi_direct kalshi_related polymarket_related claude_news gdelt_news wikipedia congress_bills code_execution

Sub-questions (Fermi decomposition)

Planner reasoning

This is a very-low-base-rate constitutional event: Section 4 of the 25th Amendment has never been invoked in US history, and it requires the VP plus a Cabinet majority to declare the President unable to serve. The market price on Kalshi is the primary anchor; the main variables are Trump's health status, any Vance/Cabinet friction, and time remaining to Jan 2029. I'll anchor on Kalshi, cross-check Polymarket, and research news on Trump's health and any 25th Amendment chatter.

# Current state Section 4 of the 25th Amendment has never been invoked in U.S. history and requires the VP + majority of Cabinet (or a Congress-designated body) to transmit a written incapacity declaration — a high, structurally difficult bar requiring GOP VP/Cabinet cooperation. Currently this remains purely a Democratic political talking point/long-shot legislative proposal (HR 8275, referred to committee 2026-04-14); there is no indication VP Vance or any Republican Cabinet member supports invocation, and official White House physician statements describe Trump as healthy aside from a diagnosed vein condition. # Timeline of key events - 2025-07-17: White House confirms Trump diagnosed with chronic venous insufficiency after leg swelling; physician rules out DVT/arterial disease (confirmed, npr.org/aljazeera.com). - 2025-10-29: Trump undergoes MRI at Walter Reed; physician calls results "perfectly normal," describes Trump as in "exceptional health" (confirmed, theweek.in). - 2025-12-01: Dr. Barbabella states annual-exam MRI showed no arterial narrowing, clotting, or acute/chronic concerns (confirmed, axios.com). - 2026-04-14: Iran-crisis rhetoric ("a whole civilization will die tonight") prompts 85+ House/Senate Democrats to call for impeachment or 25A removal; Rep. Raskin files HR 8275 to create a 17-member Section 4 capacity commission (confirmed bill filing; reported political reaction — axios.com, congress.gov). - 2026-04-20/21: Legal and medical experts (Boston Globe, STAT News) publicly argue 25A removal is a legal long-shot absent Vance/GOP buy-in and that the amendment is political, not medical (opinion/reported). - 2026-05 (per Wikipedia): Polling shows a majority of Americans doubt Trump's mental fitness (reported, poll-based, not resolution-relevant). - 2026-07-17/18: Conservative media mocks Gov. Newsom's separate 25A calls against Trump (reported, fringe political noise). - 2026-07-30/31: Alex Jones publicly calls for impeachment/25A invocation (rumored/fringe commentary, low credibility signal). - 2026-08-03/04: Vague reporting of a "secret meeting of ex-allies" amid alleged "Trump betrayal" (rumored, unconfirmed, no direct 25A linkage). # Event Will VP + Cabinet majority (or designated body) invoke Section 4 of the 25th Amendment against Trump before Jan 20, 2029? # Outcomes to forecast Yes / No # Kalshi market anchor **KXAMEND25-29 current YES price: 28.00%** — down 2pts over both 7-day and 30-day windows; 90-day range 24%-41% (has fallen substantially from a peak of 41%); average daily volume ~385 contracts (moderately liquid). This is the primary consensus to beat. # Sub-question answers 1. **Kalshi price/history** — Currently 28%, down from a 90-day high of 41%, trending down (-2% both 7d/30d). [kalshi_direct] 2. **Polymarket equivalent** — No direct Section-4 market found; closest proxy "Trump out as President by August 31 (2026)" prices YES at 0.05% (effectively zero), reflecting near-term impossibility of removal, not full-term risk. [polymarket_related] 3. **Historical base rate** — Section 4 has never been invoked in 58 years since ratification (1967); base-rate models (Jeffreys/Laplace priors) imply ~0.85%-1.67%/yr, or ~2.5%-5% over 3 years — far below current Kalshi price. [code_execution] 4. **Trump's health** — Diagnosed with chronic venous insufficiency (July 2025); Oct/Dec 2025 MRI and physician statements describe him as healthy with "exceptional" cardiovascular/neurological function; no official incapacity findings, though public reports note face drooping, bruising, and multiple "annual" exams fueling speculation. [claude_news, Wikipedia] 5. **Vance/Cabinet/Congress activity** — Rep. Raskin's HR 8275 (filed 2026-04-14) would create a Section 4 commission but has no GOP support and is stalled in committee; no evidence Vance or any Cabinet Republican has expressed willingness to invoke Section 4; experts call it a "long shot." [claude_news, congress_bills] 6. **Related markets** — Impeachment market prices 65% (much higher, easier legal bar); South Korea full-term market at 57% (unrelated comparator); Trump-family-2028-nominee at 6.6%. No market directly isolates death/resignation vs 25A share. [kalshi_related] 7. **Implied hazard** — At 28% over ~3 years, implied annualized hazard ≈11%/yr (via -ln(1-P)/3), vastly exceeding both historical base rates (~1%/yr) and conditional-pathway estimates (~0.3-3%/yr). [code_execution] # Key facts (high-confidence, factual) 1. [kalshi_direct] Current YES = 28%, falling from 41% peak over 90 days. 2. [Wikipedia] Section 4 never invoked in U.S. history; Section 3 (voluntary transfer) has been used multiple times (Reagan 1985, Bush 2002) but not 4. 3. [congress_bills] HR 8275 (Raskin) filed 2026-04-14, referred to committee, no GOP co-sponsors reported. 4. [claude_news] White House physician maintains Trump is in "exceptional health" as of Dec 2025. 5. [polymarket_related] Polymarket "Trump out by Aug 2026" priced at ~0.05% YES. # Cross-market signals - Kalshi related: Impeachment (65%) >> 25A Section 4 (28%); South Korea full-term unrelated comparator (57%). - Polymarket: Near-zero probability of near-term removal (different timeframe, not directly comparable). - Sportsbook implied: None found. # Analyst opinions and speculation - Boston Globe/STAT News (Apr 2026): 25A removal essentially requires Vance's cooperation plus ~18 GOP senators — "all but certain not to happen." [claude_news] - Democratic members (Raskin, Krishnamoorthi, Quigley, Crockett) publicly push invocation post-Iran rhetoric — political messaging, not evidence of process movement. [claude_news] - Fringe voices (Alex Jones, conservative mockery of Newsom) reflect noise, not substantive probability shift. # Directional lean per outcome - **Yes**: Elevated political rhetoric, health-related scrutiny (CVI, MRI, cognitive concerns), a filed commission bill, and a market price (28%) far above historical base rate suggest some real perceived tail risk, likely reflecting age/health uncertainty and volatile presidency. - **No**: No Section 4 precedent in 58 years; GOP controls Congress/Cabinet; Vance shows zero public support; official health reports consistently describe Trump as fit; legal experts call invocation a near-impossibility absent GOP defection. # Gaps / unknowns - No direct polling/insider reporting on Vance's private views regarding incapacity. - Unclear how much of the 28% Kalshi price reflects genuine tail risk vs. speculative/political trading given no structural progress. - HR 8275 status/floor vote unknown; no timeline for committee action. # Calibration anchors - Kalshi current YES price: 28% (down from 41%) — primary anchor. - Historical base rate models: ~2.5%-5% cumulative over 3 years (0 precedents in 58 years). - Related Kalshi impeachment market: 65% (higher, different/easier bar). - Polymarket short-term removal proxy: ~0.05% YES.

1. **Scope ambiguity unresolved**: The event title ("25th Amendment be used") is broader than the "Event" section's strict definition (Section 4 invocation only), which explicitly excludes routine Section 3 transfers (used for Reagan 1985, Bush 2002 anesthesia procedures) and Section 1 succession-on-death. Forecast 1 explicitly bakes in a Section 3/Section 1 "broader reading" (~10% actuarial mortality) to justify going above the base rate, while Forecast 2 never addresses this pathway at all yet arrives at nearly the same number — this convergence is coincidental, not a shared, principled treatment of the same ambiguity. 2. **Section 3 pathway is under-quantified, not just under-discussed**: Given Trump's age (79-82 over the term) and a diagnosed vein condition requiring monitoring, a routine anesthesia-requiring procedure (which historically triggers Section 3, not Section 4) is plausibly the single most likely "25A used" pathway if the resolution criteria are read broadly — yet neither forecaster puts an explicit probability on this scenario, they only gesture at it. 3. **The ~14-15% consensus number lacks a transparent bridge from the 2.5-5% base rate**: Both forecasters land at roughly 3-6x the historical/base-rate estimate but the stated justification (partial credit to broader reading + "favorite-longshot" market inefficiency) doesn't cleanly decompose into a number — it's unclear how much of the 15% is Section 4 risk vs. Section 3/1 risk vs. residual anchoring to Kalshi's 28%. 4. **Time-decay in the Kalshi price is not incorporated**: The market has fallen from 41% to 28% over 90 days, which is consistent with either (a) genuine risk repricing downward, or (b) mechanical decay as fewer years remain in the term (shrinking the window for any incapacity event) — neither forecast discusses whether the remaining ~2.2 years to close warrants further downward drift, which matters for point-in-time calibration. 5. **Near-identical outputs (0.15 vs 0.14) despite different reasoning chains raises overfitting-to-anchor concern**: Both models discount Kalshi's 28% to roughly half, but via different logic paths (Forecast 1: explicit scope-broadening + longshot bias; Forecast 2: hazard-rate mismatch), suggesting insufficient exploration of how far the true independent estimate should diverge from the market price rather than settling near a "half of Kalshi" heuristic.

12% (57% confidence)

Yes: 12% No: 88%

The resolution bar defined in the brief is Section 4 invocation, which has never occurred in 58 years and requires VP Vance plus a majority of a Republican Cabinet — an outcome legal analysts call 'all but certain not to happen,' with HR 8275 stalled without GOP support and physician reports describing Trump as healthy. Pure base-rate/hazard models imply only ~2.5-5% over the remaining term, so Kalshi's 28% looks inflated by favorite-longshot bias, political-narrative trading, and possible ambiguity about whether a Section 3 temporary transfer (an anesthesia-requiring procedure for an ~80-year-old) or a broader 'use' would count. I give explicit weight to that scope ambiguity: roughly 3-5% for genuine Section 4 risk plus maybe 8-10% for a broad-reading/Section 3 pathway discounted by the probability the strict definition governs, which lands modestly below both forecasters' ~14-15% and well below the market. The price's decline from 41% to 28% and shrinking remaining window argue for continued downward drift rather than reversion to the market anchor.

Total pipeline time: 205.4s